9 active not recruiting. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 9 |
Follow Adrenal Cortex Diseases: new trials by email Literature Review of Adrenal Cortex Diseases trials Research Report on Adrenal Cortex Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. Pembrolizumab 25 MG/ML [Keytruda] - Adrenocortical Carcinoma | Phase 2 | Active not recruiting | Maria Sklodowska-Curie National Research Institute of Oncology | 24 | 2023-01-31 | 2026-11-06 |
| Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Pembrolizumab / Lenvatinib - Adrenocortical Carcinoma | Phase 2 | Active not recruiting | National Cancer Center, Korea | 30 | 2021-11-15 | 2026-01-23 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome relacorilant - Cushing Syndrome | Phase 2 | Active not recruiting | Corcept Therapeutics | 125 | 2018-05-07 | 2026-11-03 |
| Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Ipilimumab, Nivolumab - Genitourinary Cancer, Adrenocortical Carcinoma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 100 | 2017-12-28 | 2026-07-23 |
| Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Cisplatin, Sodium thiosulfate, Cytoreductive surgery - Adrenocortical Carcinoma, Peritoneal Carcinomatosis | Phase 2 | Active not recruiting | Columbia University | 30 | 2017-09-22 | 2026-05-06 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 157 | 2016-08-15 | 2026-07-17 |
| Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Pembrolizumab - Adrenocortical Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 39 | 2016-02-01 | 2026-04-06 |
Adrenocortical Carcinoma (8) · Adrenal Cortex Neoplasms (2) · Carcinoma, Renal Cell (2) · Carcinoma, Small Cell (2) · Paraganglioma (2) · Penile Neoplasms (2) · Pheochromocytoma (2) · ACTH Syndrome, Ectopic (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Bile Duct Neoplasms (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1)
Adenocarcinoma (9) · Adrenal Gland Diseases (9) · Adrenal Gland Neoplasms (9) · Carcinoma (9) · Endocrine Gland Neoplasms (9) · Endocrine System Diseases (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Adrenal Cortex Neoplasms (7) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Urogenital Diseases (4)
pembrolizumab (4) · Ipilimumab (2) · Nivolumab (2) · CTLA-4 Antigen (1) · Cisplatin (1) · Cytoreduction Surgical Procedures (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · cabozantinib (1) · lenvatinib (1) · relacorilant (1) · sodium thiosulfate (1)
National Cancer Institute (NCI) (2) · Columbia University (1) · Corcept Therapeutics (1) · Dana-Farber Cancer Institute (1) · M.D. Anderson Cancer Center (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Center, Korea (1)
United States (7) · Poland (2) · Austria (1) · Canada (1) · Germany (1) · Guam (1) · Israel (1) · Italy (1) · Netherlands (1) · Romania (1) · South Korea (1) · Spain (1)
Aung Naing (1) · Bradley A McGregor, MD (1) · John McNally (1) · Kazuki Sugahara, MD, PhD (1) · Nitya Raj, MD (1) · Sandip P Patel (1) · Srivandana Akshintala (1) · Tak Yun (1)
PMID 31401903, PMID 31533818, PMID 31644329, PMID 31969335, PMID 32188704, PMID 32303619, PMID 32534809, PMID 33216356, PMID 33362722, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33770291, PMID 33882143, PMID 34241781, PMID 34380663, PMID 34716198, PMID 34725215, PMID 35618285, PMID 35999229, PMID 37568622, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40212844, PMID 40402690, PMID 40588371, PMID 41143139, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42342409, PMID 42499790
U10CA180886 (1), U10CA180888 (1)